The Vaccines Business Unit is facing a challenging landscape. We need to effectively advocate for the importance of Arexvy for everyone over 60, especially given that a significant portion of this age group has underlying conditions, as highlighted by our area VP. This is a key topic of discussion within our region, and we anticipate pushback from pharmacies and health systems on this front.
Regarding Shingrix, most individuals in the U.S. who were interested in the vaccine have already been vaccinated. The remaining opportunity lies in reaching those who are just reaching the eligible age, but this will have a minimal impact on our goals and bonuses.
Pediatric vaccines are making progress, albeit slowly. The enthusiasm for what was once seen as the 'holy grail' of adult vaccines has now diminished, leading to a more subdued outlook.
Quote